August 25, 2025 marked ZonhonBio's 14th anniversary, with the "2025 Zonhonbio & Gensunbio R&D Achievements Report Conference & Mid-Year Assessment" successfully convened in the company's multifunctional hall. All employees of Zonhonbio & Gensunbio gathered to celebrate the company’s anniversary through academic exchanges and presentations. Senior leaders from regulatory authorities, executives from Qianhong Group, and industry peers who have long supported Zonhonbio also attended the event.

The ceremony opened with Dean Ma Yong expressing sincere gratitude to all employees for their dedication and to board members and partners for their ongoing guidance. On this 14th anniversary, Dean Ma urged to uphold the corporate mission of "For Patients, for Health, for Life" and adhere to the principle of "Mastery Through Focus" emphasizing that specialization drives capability. He introduced "Consistent Excellence from Start to Finish" as the 2025 key theme, encouraging teams to maintain unwavering commitment from initial breakthroughs to ultimate goals.

Reflecting on 2015-2025 as China's golden decade for innovative drug development, he noted the concurrent rise of AI across all industries. Dean Ma announced the integration of "AI + Biopharma" into corporate strategy to accelerate AI-enabled innovation platforms and secure competitive advantages. The ceremony included recognition of employees with the "Zonhon-Kinsen Meritorious Service Award" for their longstanding dedication.

Additionally, Dean Ma announced the winners of the 2025 “Zonhonbio and Gensunbio Long-Term Service Award” and presented commemorative plaques in a recognition ceremony.

The second session featured presentations in two segments: "New Talent Forum" and "Mid-Year R&D Assessment". Four R&D newcomers shared their project progress and twenty-two representatives from R&D teams and management departments reported on project advancements and platform optimizations. Attendees engaged in lively discussions and academic exchanges during the Q&A session, fostering a dynamic atmosphere of intellectual exchange. Following the presentations, the Zonhonbio and Gensunbio Outstanding R&D Achievement Evaluation Committee convened to review submissions based on three key criteria: innovation, completion, and growth potential, and with particular emphasis on timeline & quality execution. After rigorous evaluations, the committee awarded: two “2025 Outstanding R&D Newcomer Awards” and six “2025 Outstanding R&D Achievement Awards”. A formal award ceremony was held to honor the winners.

At the conclusion of the conference, Chairman Wang Yaofang delivered a closing speech. Chairman Wang Yaofang praised the management team's scientific and standardized approach to talent development and culture building. He called on all employees to embrace rigorous pragmatism, leverage cutting-edge knowledge, and utilize AI tools to become genuine value creators during this pivotal phase of breakthrough development.

Guided by our founding mission like a torch, sharpened by purpose like a blade. During fourteen years, all people of Zonhonbio have advanced with unwavering passion for innovative drug development. The conference concluded with heartfelt acknowledgments and enthusiastic applause, commemorating both a substantial anniversary celebration and the beginning of new journeys—steadfast progress through fourteen years of refinement, embarking on distant horizons with renewed stability.